These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 16139802

  • 1. The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.
    Di Francesco AM, Riccardi A, Barone G, Rutella S, Meco D, Frapolli R, Zucchetti M, D'Incalci M, Pisano C, Carminati P, Riccardi R.
    Biochem Pharmacol; 2005 Oct 15; 70(8):1125-36. PubMed ID: 16139802
    [Abstract] [Full Text] [Related]

  • 2. Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.
    Gounder MK, Nazar AS, Saleem A, Pungaliya P, Kulkarni D, Versace R, Rubin EH.
    Invest New Drugs; 2008 Jun 15; 26(3):205-13. PubMed ID: 17943230
    [Abstract] [Full Text] [Related]

  • 3. Subcellular localization of the camptothecin analogues, topotecan and gimatecan.
    Croce AC, Bottiroli G, Supino R, Favini E, Zuco V, Zunino F.
    Biochem Pharmacol; 2004 Mar 15; 67(6):1035-45. PubMed ID: 15006540
    [Abstract] [Full Text] [Related]

  • 4. Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect.
    Prada CF, Alvarez-Velilla R, Balaña-Fouce R, Prieto C, Calvo-Álvarez E, Escudero-Martínez JM, Requena JM, Ordóñez C, Desideri A, Pérez-Pertejo Y, Reguera RM.
    Biochem Pharmacol; 2013 May 15; 85(10):1433-40. PubMed ID: 23466420
    [Abstract] [Full Text] [Related]

  • 5. Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.
    Ulivi P, Zoli W, Fabbri F, Brigliadori G, Ricotti L, Tesei A, Rosetti M, De Cesare M, Beretta GL, Corna E, Supino R, Zunino F.
    Neoplasia; 2005 Feb 15; 7(2):152-61. PubMed ID: 15802020
    [Abstract] [Full Text] [Related]

  • 6. A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo.
    Zou J, Li S, Chen Z, Lu Z, Gao J, Zou J, Lin X, Li Y, Zhang C, Shen L.
    Cell Death Dis; 2018 May 31; 9(6):661. PubMed ID: 29855512
    [Abstract] [Full Text] [Related]

  • 7. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
    Pratesi G, De Cesare M, Carenini N, Perego P, Righetti SC, Cucco C, Merlini L, Pisano C, Penco S, Carminati P, Vesci L, Zunino F.
    Clin Cancer Res; 2002 Dec 31; 8(12):3904-9. PubMed ID: 12473606
    [Abstract] [Full Text] [Related]

  • 8. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
    De Cesare M, Pratesi G, Perego P, Carenini N, Tinelli S, Merlini L, Penco S, Pisano C, Bucci F, Vesci L, Pace S, Capocasa F, Carminati P, Zunino F.
    Cancer Res; 2001 Oct 01; 61(19):7189-95. PubMed ID: 11585754
    [Abstract] [Full Text] [Related]

  • 9. Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models.
    Zuco V, Supino R, De Cesare M, Carenini N, Perego P, Gatti L, Pratesi G, Pisano C, Martinelli R, Bucci F, Zanier R, Carminati P, Zunino F.
    Biochem Pharmacol; 2003 Apr 15; 65(8):1281-94. PubMed ID: 12694869
    [Abstract] [Full Text] [Related]

  • 10. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.
    Lansiaux A, Léonce S, Kraus-Berthier L, Bal-Mahieu C, Mazinghien R, Didier S, David-Cordonnier MH, Hautefaye P, Lavielle G, Bailly C, Hickman JA, Pierré A.
    Mol Pharmacol; 2007 Aug 15; 72(2):311-9. PubMed ID: 17494837
    [Abstract] [Full Text] [Related]

  • 11. Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models.
    Meco D, Di Francesco AM, Cusano G, Bucci F, Pierri F, Patriarca V, Torella AR, Pisano C, Riccardi R.
    Cancer Chemother Pharmacol; 2012 Dec 15; 70(6):811-22. PubMed ID: 23007316
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma.
    Zuco V, Supino R, Favini E, Tortoreto M, Cincinelli R, Croce AC, Bucci F, Pisano C, Zunino F.
    Biochem Pharmacol; 2010 Feb 15; 79(4):535-41. PubMed ID: 19765546
    [Abstract] [Full Text] [Related]

  • 13. Optimized synthesis and enhanced efficacy of novel triplex-forming camptothecin derivatives based on gimatecan.
    Vekhoff P, Halby L, Oussedik K, Dallavalle S, Merlini L, Mahieu C, Lansiaux A, Bailly C, Boutorine A, Pisano C, Giannini G, Alloatti D, Arimondo PB.
    Bioconjug Chem; 2009 Apr 15; 20(4):666-72. PubMed ID: 19309124
    [Abstract] [Full Text] [Related]

  • 14. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
    Pastorino F, Loi M, Sapra P, Becherini P, Cilli M, Emionite L, Ribatti D, Greenberger LM, Horak ID, Ponzoni M.
    Clin Cancer Res; 2010 Oct 01; 16(19):4809-21. PubMed ID: 20702613
    [Abstract] [Full Text] [Related]

  • 15. DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
    Vassal G, Pondarré C, Cappelli C, Terrier-Lacombe MJ, Boland I, Morizet J, Bénard J, Vénuat AM, Ardouin P, Hartmann O, Gouyette A.
    Eur J Cancer; 1997 Oct 01; 33(12):2011-5. PubMed ID: 9516844
    [Abstract] [Full Text] [Related]

  • 16. A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma.
    Sottile F, Gnemmi I, Cantilena S, D'Acunto WC, Sala A.
    Oncotarget; 2012 May 01; 3(5):535-45. PubMed ID: 22619121
    [Abstract] [Full Text] [Related]

  • 17. Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo.
    Huang M, Gao H, Chen Y, Zhu H, Cai Y, Zhang X, Miao Z, Jiang H, Zhang J, Shen H, Lin L, Lu W, Ding J.
    Clin Cancer Res; 2007 Feb 15; 13(4):1298-307. PubMed ID: 17287296
    [Abstract] [Full Text] [Related]

  • 18. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
    Keshelava N, Groshen S, Reynolds CP.
    Cancer Chemother Pharmacol; 2000 Feb 15; 45(1):1-8. PubMed ID: 10647494
    [Abstract] [Full Text] [Related]

  • 19. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies.
    Teicher BA.
    Biochem Pharmacol; 2008 Mar 15; 75(6):1262-71. PubMed ID: 18061144
    [Abstract] [Full Text] [Related]

  • 20. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model.
    O'Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M.
    Clin Cancer Res; 1999 Jan 15; 5(1):181-7. PubMed ID: 9918217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.